ClinicalTrials.gg
CompletedNCT01640353SIFIUpdated Mar 24, 2017Results posted

Sacroiliac Joint Fusion With iFuse Implant System (SIFI)

An observational study in Degenerative Sacroiliitis and Sacroiliac Joint Disruption, sponsored by SI-BONE, Inc.. Completed at 26 sites in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-24.

Sponsored by SI-BONE, Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
194
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the use of the iFuse Implant System to treat degenerative sacroiliitis (arthritis of the SI joint) and sacroiliac disruption (abnormal separation or tearing of the sacroiliac joint). The iFuse Implant System (iFuse device) is a medical device that is surgically implanted into the sacroiliac (SI) joint during a minimally invasive surgical procedure (one that uses a smaller incision and less damage to the skin and other tissues than standard surgery). The purpose of implanting the device is to stabilize and fuse the SI joint.

02

Conditions studied

  • Degenerative Sacroiliitis
  • Sacroiliac Joint Disruption

Browse trials for

Keywords

  • si joint
  • si joint pain
  • si joint injury
  • si joint treatment
  • si joint injections
  • si joint inflammation
  • si joint problems
  • si joint symptoms
  • hypermobile si joint
  • si joint arthritis
  • si joint pain treatment
  • inflamed si joint
  • si joint sclerosis
  • locked si joint
  • si joint injuries
  • si joint disease
  • si joint infection
  • sacroiliac joint pelvic pain
  • sacroiliac joint arthritis treatment
03

In context

Sacroiliitis

42 studies on the registry are indexed under Sacroiliitis; 11 are open to participants now.

This study's enrollment of 194 is above the median of 120 across 13 observational studies indexed under Sacroiliitis.

Browse Sacroiliitis studies →

Lead sponsor

SI-BONE, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with SI joint pain due to degeneration or disruption of the SI joint

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Age 21-70 at time of screening

2. Patient has lower back pain for >6 months inadequately responsive to conservative care

3. Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following:

  1. Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and
  2. Patient has at least 3 of 5 physical examination maneuvers specific for the SI joint (see Table 3), and
  3. Patient has improvement in lower back pain numeric rating scale (NRS) of at least 50% after injection of local anesthetic into affected SI joint(s) (see Section 3.6.4), and
  4. One or more of the following:

i. SI joint disruption:

  1. Asymmetric SI joint widening on X-ray or CT scan
  2. Leakage of contrast on diagnostic arthrography

ii. Degenerative sacroiliitis:

  1. Radiographic evidence of SI joint degeneration, including sclerosis,osteophytes, subchondral cysts, or vacuum phenomenon on CT or plain film, or
  2. Due to prior lumbosacral spine fusion

4. Baseline Oswestry Disability Index (ODI) score of at least 30% 5. Baseline SI joint pain score of at least 50 on 0-100 mm visual analog scale 6. Patient has signed study-specific form 7. Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture
  2. Other known sacroiliac pathology such as:

    1. Sacral dysplasia
    2. Inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy)
    3. Tumor
    4. Infection
    5. Acute fracture
    6. Crystal arthropathy
  3. History of recent (\< 1 year) major trauma to pelvis
  4. Previously diagnosed osteoporosis (defined as prior T-score \<-2.5 or history of osteoporotic fracture).
  5. Osteomalacia or other metabolic bone disease
  6. Chronic rheumatologic condition (e.g., rheumatoid arthritis)
  7. Any condition or anatomy that makes treatment with the iFuse Implant System infeasible
  8. Chondropathy
  9. Known allergy to titanium or titanium alloys
  10. Use of medications known to have detrimental effects on bone quality and soft-tissue healing
  11. Prominent neurologic condition that would interfere with physical therapy
  12. Current local or systemic infection that raises the risk of surgery
  13. Patient currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation.
  14. Currently pregnant or planning pregnancy in the next 2 years
  15. Patient is a prisoner or a ward of the state.
  16. Known or suspected drug or alcohol abuse
  17. Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
  18. Patient is participating in an study or has been involved in an investigational study within 3 months prior to evaluation for participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
194 participants (actual)
06

What researchers measure

Primary outcomes

  1. Subject Success

    Composite endpoint of reduction from baseline in VAS back pain score by at least 20 mm, lack of device-related serious adverse events, absence of neurologic worsening and absence of surgical re-intervention.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Change in SI Joint Pain on Visual Analog Scale (VAS) (0-100 mm)

    The Visual Analog Scale (VAS) is a 100 mm line on which the subject indicates their level of pain. 0 = no pain. 100 = worst imaginable pain.

    Time frame: 24 months

  2. Change in Back Dysfunction

    Oswestry Disability Index is a validated patient questionnaire aiming to assess low back pain. The computed scores can be 0% to 100%. Lower scores indicate low disability while high scores indicate high disability. There are 10 questions on the questionnaire. Each has 6 possible answers (0 points - 5 points). If the question is skipped, it's points are subtracted from the denominator. If the raw score is 30 and all 10 questions were answered, the calculation would be 30 / 50 = 60%. If one question was skipped, it would be 30 / 45 = 67%.

    Time frame: 24 months

  3. Change in Quality of Life

    Change in QOL as measured by Short Form-36 PCS and EQ-5D at post-operative visits

    Time frame: Baseline and 24 months

  4. Ambulatory Status

    Percentage of population fully ambulatory at 24 months post operatively.

    Time frame: 24 months

  5. Work Status

    Proportion of non-working subjects who return to work

    Time frame: Basline, 24 months

  6. Serious Adverse Events

    Occurrence of adverse events meeting the ISO14155:2011 definition of serious occurring during the procedure, at the time of hospital discharge (typically day of or next day after procedure), and at various times in late follow-up.

    Time frame: Procedure, discharge, 1,3,6,12,18 and 24 months

07

Results

Posted Mar 24, 2017
Limitations and caveats
Lack of concurrent control group undergoing non-surgical treatment and a 24-month follow up rate that was not as high as desired.

Participant flow

Participant flow — Overall Study
MilestoneSacroiliac Joint Fusion
Started194
Treated172
Month 1171
Month 3169
Month 6168
Month 12160
Month 18150
Completed149
Not completed45
Withdrew: Withdrew prior to treatment10
Withdrew: Withdrawn from analysis at term site12
Withdrew: Withdrawal by subject5
Withdrew: Death2
Withdrew: Early site termination3
Withdrew: Lost to follow-up12
Withdrew: Physician decision1

Outcome measures

PrimarySubject Success

Composite endpoint of reduction from baseline in VAS back pain score by at least 20 mm, lack of device-related serious adverse events, absence of neurologic worsening and absence of surgical re-intervention.

Time frame:
Baseline and 6 months
Reported as:
Number · percentage of participants
Subject Success
percentage of participantsSacroiliac Joint Fusion
Subject Success80.5 (74.0 to 85.9)
SecondaryChange in SI Joint Pain on Visual Analog Scale (VAS) (0-100 mm)

The Visual Analog Scale (VAS) is a 100 mm line on which the subject indicates their level of pain. 0 = no pain. 100 = worst imaginable pain.

Time frame:
24 months
Reported as:
Mean · units on a scale
Change in SI Joint Pain on Visual Analog Scale (VAS) (0-100 mm)
units on a scaleSacroiliac Joint Fusion
Change in SI Joint Pain on Visual Analog Scale (VAS) (0-100 mm)53.3 ± 27.6
SecondaryChange in Back Dysfunction

Oswestry Disability Index is a validated patient questionnaire aiming to assess low back pain. The computed scores can be 0% to 100%. Lower scores indicate low disability while high scores indicate high disability. There are 10 questions on the questionnaire. Each has 6 possible answers (0 points - 5 points). If the question is skipped, it's points are subtracted from the denominator. If the raw score is 30 and all 10 questions were answered, the calculation would be 30 / 50 = 60%. If one question was skipped, it would be 30 / 45 = 67%.

Time frame:
24 months
Reported as:
Mean · units on a scale
Change in Back Dysfunction
units on a scaleSacroiliac Joint Fusion
Change in Back Dysfunction24.5 ± 21.1
SecondaryChange in Quality of Life

Change in QOL as measured by Short Form-36 PCS and EQ-5D at post-operative visits

Time frame:
Baseline and 24 months
Reported as:
Mean · units on a scale
Change in Quality of Life
units on a scaleSacroiliac Joint Fusion
SF36 PCS8.9 ± 10.6
SF36 MCS10.1 ± 11.8
EQ5D TTO.27 ± .26
SecondaryAmbulatory Status

Percentage of population fully ambulatory at 24 months post operatively.

Time frame:
24 months
Reported as:
Number · percentage of participants
Ambulatory Status
percentage of participantsSacroiliac Joint Fusion
Ambulatory Status89.2
SecondaryWork Status

Proportion of non-working subjects who return to work

Time frame:
Basline, 24 months
Reported as:
Number · percentage of participants
Work Status
percentage of participantsSacroiliac Joint Fusion
Work Status25.0
SecondarySerious Adverse Events

Occurrence of adverse events meeting the ISO14155:2011 definition of serious occurring during the procedure, at the time of hospital discharge (typically day of or next day after procedure), and at various times in late follow-up.

Time frame:
Procedure, discharge, 1,3,6,12,18 and 24 months
Reported as:
Number · serious adverse event
Serious Adverse Events
serious adverse eventSacroiliac Joint Fusion
Serious Adverse Events100

Adverse events

Collected over 1 month, 3 months, 6 months, 12 months, 18 months, 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sacroiliac Joint Fusion—67/172 (39%)153/172 (89%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventSacroiliac Joint Fusion
Degenerative disease - spineMusculoskeletal and connective tissue disorders12/172
Contralateral SIJ painMusculoskeletal and connective tissue disorders8/172
Back painMusculoskeletal and connective tissue disorders5/172
Rotator cuff tearMusculoskeletal and connective tissue disorders3/172
Shoulder painMusculoskeletal and connective tissue disorders3/172
Revision - SIJ painInjury, poisoning and procedural complications3/172
PneumoniaRespiratory, thoracic and mediastinal disorders3/172
Neck painMusculoskeletal and connective tissue disorders2/172
Osteoarthritis of the hipMusculoskeletal and connective tissue disorders2/172
Vertebral compression fractureMusculoskeletal and connective tissue disorders2/172
Most frequent other events
Showing 10 of 146
Most frequent other events
EventSacroiliac Joint Fusion
Back painMusculoskeletal and connective tissue disorders34/172
Degenerative disease - spineMusculoskeletal and connective tissue disorders28/172
Ipsilateral SIJ painMusculoskeletal and connective tissue disorders21/172
Buttock painMusculoskeletal and connective tissue disorders19/172
Contralateral SIJ painMusculoskeletal and connective tissue disorders18/172
Hip painMusculoskeletal and connective tissue disorders9/172
Trochanteric bursitisMusculoskeletal and connective tissue disorders9/172
Knee painMusculoskeletal and connective tissue disorders7/172
Upper respiratory infectionRespiratory, thoracic and mediastinal disorders7/172
UTIRenal and urinary disorders5/172

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sacroiliac Joint Fusion
Mean50.9 (23.5 to 71.6)
Sex: Female, Male
Sex: Female, Male(Participants)Sacroiliac Joint Fusion
Female120
Male52
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sacroiliac Joint Fusion
Hispanic or Latino7
Not Hispanic or Latino165
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sacroiliac Joint Fusion
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American2
White166
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)Sacroiliac Joint Fusion
United States172
Baseline SIJ pain
Baseline SIJ pain(units on a scale)Sacroiliac Joint Fusion
Mean79.8 ± 12.8
Baseline ODI
Baseline ODI(units on a scale)Sacroiliac Joint Fusion
Mean55.2 ± 11.5
Baseline EQ-5D
Baseline EQ-5D(units on a scale)Sacroiliac Joint Fusion
Mean.43 ± 0.18

3 further baseline measures are reported on the registry.

08

Study locations

26 sites
  • Spine and Neuro Center
    Huntsville, Alabama 35801, United States
  • Silicon Valley Spine
    Campbell, California 95008, United States
  • BASIC Spine
    Newport Beach, California 92660, United States
  • Southern California Center for Neuroscience and Spine (SCCNS)
    Pomona, California 91767, United States
  • St. Mary's Spine
    San Francisco, California 94117, United States
  • Neurosurgical and Spine Specialists
    Parker, Colorado 80138, United States
  • Orthopaedic Clinic of Daytona Beach
    Daytona Beach, Florida 32117, United States
  • The Orthopaedic Institute/NFRMC
    Gainsville, Florida 32607, United States
  • Bartow Regional Medical Center
    Lakeland, Florida 33806, United States
  • Piedmont Orhopaedics
    Macon, Georgia 31210, United States
  • Orthopaedic Center of Southern Illinois
    Mount Vernon, Illinois 62864, United States
  • Bluegrass Orthopaedics & Hand Care Research
    Lexington, Kentucky 40509, United States
  • Columbia Orthopaedic Group
    Columbia, Missouri 65201, United States
  • Midwest Division-RMC, LLC,-Research Medical Center
    Kansas City, Missouri 64132, United States
  • Mercy Medical Research Institute
    Springfield, Missouri 65807, United States
  • Alice Peck Day Memorial Hospital
    Lebanon, New Hampshire 03766, United States
  • Manhattan Orthopedic Spine, PLLC
    New York, New York 10075, United States
  • Orthopedic and Reconstructive Center (formally)Health Research Institute
    Oklahoma City, Oklahoma 73109, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • East Tennesse Brain & Spine Center
    Johnson City, Tennessee 37064, United States
  • Brazos Spine
    College Station, Texas 77845, United States
  • Texas Back Institute
    Plano, Texas 75093, United States
  • Precision Spine Care
    Tyler, Texas 75701, United States
  • Virginia Spine Institute
    Reston, Virginia 20190, United States
  • Overlake Hospital Medical Center
    Bellevue, Washington 98004, United States
09

References and documents

Publications

  • Dat KO, Cher D, Polly DW. Effects of BMI on SI joint fusion outcomes: examining the evidence to improve insurance guidelines. Spine J. 2024 May;24(5):783-790. doi: 10.1016/j.spinee.2023.11.015. Epub 2023 Dec 9. PubMed 38081463 ↗

Individual participant data

Plan to share: Yes — Data is shared with YODA project.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jan 2015 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2012
First posted
Jul 13, 2012
Start
Jul 2012
Primary completionActual
Jan 2015
CompletionActual
Feb 2016
Results first posted
Mar 24, 2017
Last update
Mar 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01640353
Lead sponsor
SI-BONE, Inc.
Responsible party
Sponsor
First posted
Jul 13, 2012
Start date
Jul 2012
Primary completion
Jan 2015
Completion
Feb 2016
Results posted
Mar 24, 2017
Last update
Mar 24, 2017

Study contacts

Bradley Duhon, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion